Spark Therapeutics Inc (ONCE) : Cqs Cayman Lp added new position in Spark Therapeutics Inc during the most recent quarter end. The investment management firm now holds 134,669 shares of Spark Therapeutics Inc which is valued at $7,783,868 , the company said in a statement filed on Aug 9, 2016 with the SEC.Spark Therapeutics Inc makes up approximately 1.80% of Cqs Cayman Lp’s portfolio.
Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in ONCE in the latest quarter, The investment management firm added 299 additional shares and now holds a total of 2,432 shares of Spark Therapeutics Inc which is valued at $140,570.Td Asset Management Inc boosted its stake in ONCE in the latest quarter, The investment management firm added 3,064 additional shares and now holds a total of 68,851 shares of Spark Therapeutics Inc which is valued at $4,107,651. Spark Therapeutics Inc makes up approx 0.01% of Td Asset Management Inc’s portfolio. State Board Of Administration Of Florida Retirement System added ONCE to its portfolio by purchasing 6,004 company shares during the most recent quarter which is valued at $358,199.California State Teachers Retirement System boosted its stake in ONCE in the latest quarter, The investment management firm added 17,165 additional shares and now holds a total of 35,988 shares of Spark Therapeutics Inc which is valued at $2,155,681.Creative Planning reduced its stake in ONCE by selling 25 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 10,500 shares of ONCE which is valued at $555,660.
Spark Therapeutics Inc closed down -1.2 points or -2.02% at $58.09 with 4,30,003 shares getting traded on Wednesday. Post opening the session at $59.24, the shares hit an intraday low of $56.88 and an intraday high of $60.08 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Spark Therapeutics Inc reported $-1.04 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.99. The company had revenue of $1.29 million for the quarter, compared to analysts expectations of $1.30 million. During the same quarter in the previous year, the company posted $-0.60 EPS.
Many Wall Street Analysts have commented on Spark Therapeutics Inc. RBC Capital Mkts Initiated Spark Therapeutics Inc on Jul 12, 2016 to “Outperform”, Price Target of the shares are set at $70.Shares were Reiterated by Cantor Fitzgerald on Jun 23, 2016 to “Buy” and Lowered the Price Target to $ 94 from a previous price target of $100 .Company shares were Reiterated by SunTrust on Jun 21, 2016 to “Buy”, Firm has raised the Price Target to $ 72 from a previous price target of $64 .
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.